ÁNGELES PEÑUELAS
Supervisor

Clinical trials in oncology are essential for both the identification of new, more effective therapies for cancer as well as improving outcomes such as survival, side effect profiles, combination therapies and quality of life.

Such advances in cancer care and the development of more effective cancer therapeutics depend on an optimal clinical trial process.

Clinical Research Oncology Nurses play a key role in that process by assuming a variety of roles including identifying trends in side effects, collaborating with multidisciplinary teams to develop and evaluate patient management, contributing to the scientific process by collating samples and quality data as well as providing excellence in nursing care and symptom management of trial participants.

VHIO’s Clinical Research Oncology Nurses, specialized in molecular therapies, are headed by Angeles Peñuelas and represent a critical and expert element of the multidisciplinary oncology team involved in clinical trials peformed and coordinated at VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – ”la Caixa” and Clinical Trials Office, directed by Jordi Rodón, also Principal Investigator of VHIO’s Early Clinical Drug Development Group, and Gemma Sala, respectively.

Supporting these expert multidisciplinary teams comprised of medical oncologists, molecular pathologists, oncology pharmacists, clinical researchers and study coordinators, VHIO’s clinical research oncology nurses play a central role in ensuring the delivery of optimal care whereby patients receive the full range of expertise, guidance, and necessary follow-up throughout the course of their enrolment in a particular clinical study.

In 2015, across the 289 actively recruiting trials, patient enrolment totaled at 979, and, in addition, we continue to follow up all patients that were recruited prior to 2015 who are still enrolled and receiving treatment.

As VHIO continues to expand its portfolio of clinical trials in order to ultimately establish novel treatments with highly selective drugs, and its research teams collaborate in close connectivity to fine-tune patient selection criteria in order to identify those patients who are most likely to benefit from them, we can expect a steady increase in patient recruitment across our clinical studies — now and in the future.


TEAM


  • Supervisor
    • Ángeles Peñuelas
  • Nurse Coordinators
    • Sonia Valverde
    • Lydia Vélez
  • Nurses
    • Elena de Cabo
    • Irene Calzado
    • Alberto Cruz
    • Mertixell Cucurell
    • Carla Junyent
    • Isabel Mari Magallon
    • Margarida Marcos
    • Cristina Martínez
    • Marta Mate
    • Núria Membrives
    • Mireia Milán
    • Isabel Muñoz
    • Sivia Puyalto
    • Laura Rabuñal
    • Tania Sánchez
    • Alex Sierra
    • Lidia Vegas
    • Natassia Ann Wornhan
  • Nursing Assistants
    • Alicia López
    • Gema Fernanda López
    • Mª Ascension Martín
    • Ana Belen Ortiz
  • Nurse Supervisor´s Assistant
    • Juan Manuel Garcia
  • Secretary
    • Mª Teresa Mendoza